In a groundbreaking study conducted by researchers from the University College London and the Royal Free Hospital in the UK, three men with a fatal heart condition experienced a remarkable reversal of their symptoms. The condition, known as transthyretin cardiac amyloidosis, is caused by the accumulation of sticky and toxic proteins in the heart. Until now, it has been considered as a progressive and irreversible disease, with a high mortality rate within four years of diagnosis.
The three men, aged 68, 76, and 82, were diagnosed with transthyretin cardiac amyloidosis and were enrolled in the study. The researchers closely monitored their progress and documented significant improvements in their health. Their findings were published as a letter in The New England Journal of Medicine.
To confirm the men's recoveries, the researchers utilized various diagnostic tools, including blood tests and imaging techniques such as echocardiography and cardiovascular magnetic resonance (CMR) scans. These tests revealed that the buildup of amyloid proteins in the heart had disappeared, and the structure and function of the heart had returned to a near-normal state. Additionally, scintigraphy and exercise capacity assessments further supported the evidence of improvement.
Also Read: How stress ups risk of cancer, heart disease
Lead author Professor Marianna Fontana from UCL's Division of Medicine expressed the significance of the study's findings, stating, "We have seen for the first time that the heart can get better with this disease. That has not been known until now and it raises the bar for what might be possible with new treatments."
The researchers also made a noteworthy discovery related to the immune response of the three men. They found evidence of antibodies specifically targeting the amyloid proteins, which were absent in other patients whose conditions progressed as expected. Although the exact causal relationship between these antibodies and the recovery remains to be conclusively proven, Professor Julian Gillmore, head of the UCL Centre for Amyloidosis, suggested that there is potential for these antibodies to be recreated in a lab and used as a therapeutic approach.
Whereas, Professor Gillmore emphasised that further investigation is required, and the research is still at a preliminary stage. However, if the antibodies could be harnessed, they could be combined with ongoing trials of new therapies that suppress the production of transthyretin (TTR) protein. This combination approach may enable clinicians to not only clear away existing amyloid but also prevent further deposition, providing hope for future treatments.
The study's findings present a promising breakthrough in the field of cardiac amyloidosis, offering new insights into the potential for reversing this once-deemed irreversible condition. The possibility of harnessing antibodies and combining them with targeted therapies has raised hopes for improved treatment options for patients in the future.
Also Read: New lab grown mini heart chamber may help speed heart disease cures